ReviewRadiology2023
LI-RADS: Looking Back, Looking Forward.
Review in Radiology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Expert consensus regarding the clinical application of liver contrast-enhanced US with Sonazoid (Sonazoid CEUS).International journal of surgery (London, England) · 2026Guideline
- Performance of LI-RADS category 5 vs combined categories 4 and 5: a systemic review and meta-analysis.European radiology · 2024Pooled it
- Contrast-enhanced US of High-Risk Indeterminate Focal Liver Observations Categorized as LR-4 or LR-M at CT/MRI.Radiology · 2025Trial
- MRI risk stratification in metabolic dysfunction-associated steatotic liver disease (MASLD): from diffuse liver disease to focal lesions.Abdominal radiology (New York) · 2026Review
- Response evaluation to systemic therapy in HCC: Current challenges and future perspectives.Hepatology (Baltimore, Md.) · 2026Review
- Hepatobiliary phase imaging in HCC: revisiting diagnostic algorithms and clinical utility of gadoxetic acid-enhanced MRI across international guidelines.Insights into imaging · 2026Review
- Baseline CT imaging features combined with clinical indicators predict prognosis in unresectable HCC treated with HAIC plus targeted therapy and immunotherapy.Abdominal radiology (New York) · 2026Article
- Indeterminate CT reporting of adult acute appendicitis: radiologist versus lexicon-based diagnostic certainty.Insights into imaging · 2026Article
- The value of LI-RADS ancillary features and biomarker for hepatocellular carcinoma ≤ 30 mm in Western and Eastern guidelines on extracellular agent and gadoxetic acid-enhanced MRI.European radiology · 2026Article
- Review
- LI-RADS v2018 versus KLCA-NCC v2022: comparison of probability-based HCC categories.European radiology · 2026Article
- Comparison of Annual Dynamic Abbreviated MRI and Biannual Ultrasound for HCC Surveillance in a High-Risk Group: Two-Center Cohort Study.Liver cancer · 2026Article
- The 2024 LI-RADS treatment response update: practical reporting after non-radiation and radiation locoregional therapies for hepatocellular carcinoma.Insights into imaging · 2026Review
- Article
- The disguised liver abscess closely resembled diffuse hepatocellular carcinoma with portal vein tumor thrombus: a case description and literature analysis.Quantitative imaging in medicine and surgery · 2026Article
- Artificial intelligence in imaging diagnosis of liver tumors: current status and future prospects.Abdominal radiology (New York) · 2026Review
- Artificial Intelligence and Radiomics in Primary Liver Cancer Imaging: A Bibliometric and Visualized Analysis.Journal of hepatocellular carcinoma · 2026Article
- Knowledge, attitudes and current practices regarding LI-RADSSA journal of radiology · 2026Article
- A Case Report of an Inflammatory Hepatocellular Adenoma Mimicking Hepatocellular Carcinoma in a Patient with Alcoholic Cirrhosis.Current medical imaging · 2026Article
- Ethical challenges and governance of artificial intelligence in hepatocellular carcinoma management : Wan DL et al. Ethical considerations in AI for hepatocellular carcinoma.Medical oncology (Northwood, London, England) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Since its initial release in 2011, the Liver Imaging Reporting and Data System (LI-RADS) has evolved and expanded in scope. It started as a single algorithm for hepatocellular carcinoma (HCC) diagnosis with CT or MRI with extracellular contrast agents and has grown into a multialgorithm network covering all major liver imaging modalities and contexts of use. Furthermore, it has developed its own lexicon, report templates, and supplementary materials. This article highlights the major achievements of LI-RADS in the past 11 years, including adoption in clinical care and research across the globe, and complete unification of HCC diagnostic systems in the United States. Additionally, the authors discuss current gaps in knowledge, which include challenges in surveillance, diagnostic population definition, perceived complexity, limited sensitivity of LR-5 (definite HCC) category, management implications of indeterminate observations, challenges in reporting, and treatment response assessment following radiation-based therapies and systemic treatments. Finally, the authors discuss future directions, which will focus on mitigating the current challenges and incorporating advanced technologies. Tha authors envision that LI-RADS will ultimately transform into a probability-based system for diagnosis and prognostication of liver cancers that will integrate patient characteristics and quantitative imaging features, while accounting for imaging modality and contrast agent.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.